Market Data 
Markets
Replies to post #618578 on NorthWest Biotherapeutics Inc (NWBO)
08/08/23 5:29 PM
08/08/23 5:35 PM
08/08/23 9:46 PM
but I really don't think LP has some sort of master plan to trap the shorts. She likely has her hands full getting the MAA application across the line.
Question 5: Can NWBO overcome all of the forces that are aligned against them?
Answer (LG): "We're still here. Lots of people didn't think we would be."
(LP) "I can only give a couple of comments from a personal perspective. Everyone in this company is committed in a deeply personal way to this company and this technology, for whatever their respective, personal reasons are. Nobody would go through this degree of abuse for this long a period of time for a business, and certainly not to collect a salary paycheck, as is regularly suggested on the message boards. I personally think that if we could get through what we've gone through the last three years, I kind of think we can get through anything. The year 2015, we had come out . . . we had just made very strong
with the anonymous Internet report, we were hit with an attempted hostile takeover. We were hit with just incredible things. When we look back on it now, it's just amazing.
In 2016 and 2017, were pretty horrific in their own way. And I've must say, this team, everything we do we do as a team. We do everything by unanimity. Management and the board, we have just kept doggedly putting one foot in front of the other. And we do say to ourselves not infrequently, 'well, we're not dead yet
And we take satisfaction in the fact that somewhere there's a conference room with the bad guys in it who are saying to themselves, what does it take to kill these people?'
Because what's been thrown at us, stock manipulation, you name it, is staggering.
But, this team will never give up. We might be crushed like a bug but we will never give up
And at this point, with the dataset . . . I hope everyone can appreciate the year 2018. The year 2018, at least in my perspective, was really transformative for us. We came out with two sets of interim data from the clinical trial. It's not the final data, it's not unblinded. The future may look different. That's a classic forward-looking statement. But that interim data was .we are up against."
(LG): "I only have one other thought, which I give a lot of thought to actually. In the context of your point about 'with the better our stuff gets the tougher and meaner the other guys get,' there's another word that goes with tougher and meaner and it's more brazen. [color=red]And the more brazen they get, maybe they're walking into a trap. That's as far as I'm going to go, because they have been . . . we have to be conservative in what we say . . . we'll use the word 'outlandish' in how brazen they've been and the better our stuff gets, the more obvious they're going to have to get and at some point, if you have built the right things that I was talking about before, with investor relations and media and you're getting the story out there about the little engine who could, there will become a tipping point, I sincerely believe, that they'll do themselves in. And we want to be there to catch it, and that's all I'll say about it but it isn't just a one-way street where they rule the world, it gets tougher and tougher the better we get and that provides angles we can work with."
AI
